MAPT and Alzheimer disease: Additionally, elevated levels of TMAO in CSF are correlated with the presence of biomarkers associated with AD pathology, such as phosphorylated tau and phosphorylated tau/A β42, as well as biomarkers of neuronal degeneration, such as total tau and neurofilament light chain protein [92].